癌症基因治療市場規模、佔有率及成長分析（按類型、治療方法、產品、最終用途和地區）－2025-2032 年產業預測

預計 2023 年全球癌症基因治療市場規模將達到 35 億美元，從 2024 年的 42.5 億美元成長到 2032 年的 200.5 億美元，預測期內（2025-2032 年）的複合年成長率為 21.4%。

全球癌症發生率的上升對癌症基因治療市場的成長產生了重大影響。主要促進因素包括對創新癌症治療的需求不斷增加、基因工程技術的進步以及對開發新治療方法的大量投資。由於正在進行的腫瘤學研究以及對個人化治療方案以提高存活率的需求，公司正在優先開發新的基因療法。此外，政府對癌症患者的支持為治療提供者創造了更多機會。然而，高昂的治療成本、潛在的副作用以及製造障礙等挑戰可能會限制市場的長期發展潛力。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

癌症基因治療市場規模（按類型及複合年成長率）（2025-2032）

• 市場概覽
• 體外
• 體內

癌症基因治療市場規模（按治療方法類型和複合年成長率）（2025-2032）

• 市場概覽
• 溶瘤病毒療法
• 基因導向免疫治療
• 基因轉移

癌症基因治療市場規模（按產品和複合年成長率） (2025-2032)

• 市場概覽
• 病毒載體
  • 腺病毒
  • 慢病毒
  • 逆轉錄病毒
  • 腺結合病毒
  • 單純皰疹病毒
  • 痘苗病毒
  • 其他病毒載體
• 非病毒載體
• 其他產品

癌症基因治療市場規模（按最終用途和複合年成長率） (2025-2032)

• 市場概覽
• 生物製藥公司
• 研究組織
• 其他最終用途

癌症基因治療市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Novartis AG（Switzerland）
• Gilead Sciences, Inc.（USA）
• Bristol Myers Squibb Company（USA）
• CRISPR Therapeutics（Switzerland）
• Amgen Inc.（USA）
• Merck KGaA（Germany）
• Intellia Therapeutics, Inc.（USA）
• Adaptimmune Therapeutics（UK）
• Autolus Therapeutics（UK）
• Sangamo Therapeutics, Inc.（USA）
• Vertex Pharmaceuticals（USA）
• Abeona Therapeutics Inc.（USA）
• Johnson & Johnson（USA）
• Pfizer Inc.（USA）
• AstraZeneca（UK）
• Takeda Pharmaceutical Company Limited（Japan）

結論和建議

Global Cancer Gene Therapy Market size was valued at USD 3.5 billion in 2023 and is poised to grow from USD 4.25 billion in 2024 to USD 20.05 billion by 2032, growing at a CAGR of 21.4% during the forecast period (2025-2032).

The rising global incidence of cancer is significantly influencing the growth of the cancer gene therapy market. Key drivers include an increasing demand for innovative cancer treatments, advancements in genetic engineering technologies, and substantial investments directed towards the development of novel therapies. Companies are prioritizing the creation of new gene therapies fueled by ongoing research in oncology and the desire for personalized treatment options, which aim to enhance survival rates. Moreover, government support for cancer patients presents additional opportunities for therapy providers. However, challenges such as the high cost of treatments, the potential for adverse effects, and manufacturing hurdles could limit the market's long-term development potential.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Gene Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Gene Therapy Market Segments Analysis

Global Cancer Gene Therapy Market is segmented by Type, Therapy, Product, End Use and region. Based on Type, the market is segmented into Ex-Vivo and In-Vivo. Based on Therapy, the market is segmented into Oncolytic Virotherapy, Gene-Induced Immunotherapy and Gene Transfer. Based on Product, the market is segmented into Viral Vectors, Non-Viral Vectors and Other Products. Based on End Use, the market is segmented into Biopharma Companies, Research Institutes and Other End-Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cancer Gene Therapy Market

The Global Cancer Gene Therapy market is significantly propelled by advancements in genetic engineering and genome mapping technologies, which have seen substantial investments in gene research initiatives. These breakthroughs in genetics are increasingly converging with oncology research, leading to the development of innovative cancer gene therapies. This integration not only enhances treatment options but also stimulates market expansion, reflecting the growing importance of personalized medicine in addressing complex cancer challenges. As these technologies evolve, they are set to further accelerate the growth of the cancer gene therapy sector, ultimately striving to improve patient outcomes and revolutionize cancer treatment methodologies.

Restraints in the Global Cancer Gene Therapy Market

The Global Cancer Gene Therapy market faces significant restraints primarily due to the high costs associated with these advanced treatments. The expenses incurred from sophisticated equipment and thorough research and development processes make gene therapy inaccessible for many cancer patients. These financial barriers hinder the widespread adoption of cancer gene therapy, as not all patients can afford the treatment. Consequently, the high pricing remains a critical factor that limits the potential growth of the market, as cost-effective alternatives are often sought in the pursuit of effective cancer therapies. This economic limitation poses challenges for both patients and healthcare providers in accessing these innovative solutions.

Market Trends of the Global Cancer Gene Therapy Market

The Global Cancer Gene Therapy market is witnessing a significant trend toward the growing demand for combination therapies, driven by an increasing number of cancer patients seeking enhanced survival rates and improved treatment outcomes. This shift presents a strategic opportunity for cancer gene therapy providers to innovate and expand their offerings by developing novel combination therapies that synergistically leverage the effects of various treatment modalities, such as targeted therapies, immunotherapies, and traditional chemotherapies. By prioritizing research and collaboration, these providers can not only address the evolving needs of patients but also maximize their market potential and reinforce their competitive edge in the long-term landscape of oncology.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Cancer Gene Therapy Market Size by Type & CAGR (2025-2032)

• Market Overview
• Ex-Vivo
• In-Vivo

Global Cancer Gene Therapy Market Size by Therapy & CAGR (2025-2032)

• Market Overview
• Oncolytic Virotherapy
• Gene-Induced Immunotherapy
• Gene Transfer

Global Cancer Gene Therapy Market Size by Product & CAGR (2025-2032)

• Market Overview
• Viral Vectors
  • Adenoviruses
  • Lentiviruses
  • Retrovirus
  • Adeno Associated Virus
  • Herpes Simplex Virus
  • Vaccinia Virus
  • Other Viral Vectors
• Non-Viral Vectors
• Other Products

Global Cancer Gene Therapy Market Size by End Use & CAGR (2025-2032)

• Market Overview
• Biopharma Companies
• Research Institutes
• Other End-Users

Global Cancer Gene Therapy Market Size & CAGR (2025-2032)

• North America (Type, Therapy, Product, End Use)
  • US
  • Canada
• Europe (Type, Therapy, Product, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Therapy, Product, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Therapy, Product, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Therapy, Product, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CRISPR Therapeutics (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intellia Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adaptimmune Therapeutics (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Autolus Therapeutics (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sangamo Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertex Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abeona Therapeutics Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations